FONT-SIZE Plus   Neg

Active Biotech, Ipsen Present OS Data From Tasquinimod Phase II Study In CRPC

Active Biotech (ATVBF.PK) and Ipsen presented overall survival, or OS, data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer, or CRPC.

The intention-to-treat analysis showed median overall survival times of 33.4 vs. 30.4 months in favor of tasquinimod, longer than previously reported in this metastatic prostate cancer population. A stronger trend for survival benefit is observed in patients with bone metastases. This phase II clinical trial was designed to test the safety and efficacy of tasquinimod.

Noteworthy, 41 patients crossed-over from placebo to tasquinimod. Besides, there were imbalances in baseline prognostic factor in favor of the placebo arm. These were addressed with a multivariate analysis of known CRPC prognostic factors. It showed a statistically significant OS advantage for tasquinimod treated patients with a hazard ratio of 0.64, a decrease of around 40% in the instantaneous risk of event (death), accompanied by improvement in progression-free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German conglomerate Bayer AG, which is in $66 billion deal to acquire U.S. seed firm Monsanto Co., on Wednesday raised its core earnings forecast for fiscal 2016 after reporting higher profit and sales in its third quarter. Further, the company maintained guidance for adjusted EBITDA, a key earnings metric, and sales. The stock is currently trading 3 percent lower in Germany. Aerospace and defense major Airbus Group SE Wednesday reported a decline in nine-month profit and new orders, while revenues were stable. The weak results reflected the ongoing ramp-up and transition from current to new aircraft models. Looking ahead, for fiscal 2016, the company continues to expect stable adjusted earnings per share and EBIT. Apple Inc. (AAPL) reported its third straight quarter of iPhone sales and revenue declines after the market closed on Tuesday. The tech giant's fourth-quarter profit trumped Wall Street expectations, while revenues fell short. Although, Apple reported its third straight year-over-year decline in iPhone...
comments powered by Disqus
Follow RTT